

# CSL™ ASX Announcement

**For immediate release**

December 23, 2009

## **CSL LIMITED AND NATIONAL BLOOD AUTHORITY SIGN NEW AUSTRALIAN FRACTIONATION AGREEMENT**

CSL Limited (ASX: CSL) announced today that it has signed an agreement with the National Blood Authority, acting on behalf of both State and Commonwealth Governments, to continue to provide the Australian community with safe, secure and affordable plasma therapeutic products.

“CSL welcomes the opportunity to continue our longstanding commitment to provide plasma derived therapeutic products for use by Australians living with serious medical conditions”, Managing Director and Chief Executive Officer of CSL Limited, Dr Brian McNamee said today.

“The Agreement provides the Australian public with a secure supply of plasma-derived medicines of the highest safety and quality over the life of the Agreement”, he said.

Under the new Agreement, CSL will continue to supply a broad range of plasma therapeutics manufactured exclusively at its Broadmeadows, Victoria, production facility from plasma provided by the Australian Red Cross Blood Service.

The Agreement also supports the important, long standing collaboration between CSL and the Australian Red Cross Blood Service, for the fractionation of plasma supplied through the efforts of volunteer donors. This collaboration ensures that Australians will continue to have secure, safe and prompt access to a comprehensive range of plasma-derived medical treatments.

The new Agreement will commence on 1 January 2010 and will run for a total of eight years until 31 December 2017, subject to the satisfactory completion of a review against specified criteria to be undertaken during year five.

**For more information about CSL Limited, visit [www.csl.com.au](http://www.csl.com.au)**

### **Media Contact**

Ms Pippa McIntosh  
Senior Communications Manager, CSL Limited  
Mobile: 03 9389 1756 or 0434 565 163  
Email: [pippa.mcintosh@csl.com.au](mailto:pippa.mcintosh@csl.com.au)